Navigation Links
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Date:11/14/2012

re evaluable at the six-month follow-up. The complete response rate at six months among basal cell carcinomas was 92.8 percent and 70 percent among squamous cell carcinomas. Response rate of melanoma was not calculated since multiple tumors were treated with concomitant therapy. The treatment was well-tolerated. The most frequent treatment-related adverse events were pain, infection and insomnia; all were transient and manageable. 

NeoPulse appears well-tolerated and able to achieve local control comparable to that of surgical resection. The potential advantage of the therapy lies with the preservation of normal tissue with improved cosmesis, avoiding the need for reconstruction in difficult-to-treat sites or those with significant innervation. Together with the possible reduction in cost associated with hospitalization for procedures involving extensive reconstruction, the approach warrants further exploration as an alternative in select cases of skin cancer.

Punit Dhillon, President and CEO of OncoSec Medical, said, "These data demonstrate how NeoPulse might serve as an alternative to surgery that selectively destroys cancer cells without harming normal, healthy tissue. The results of OncoSec's skin cancer program have so far shown a positive outcome among the class of patients who would typically be subjected to disfiguring surgery. We believe that NeoPulse offers a potentially significant new treatment for a variety of skin cancers."

About the Phase IV Study

This Phase IV study was designed as an open-labeled study to measure local control and pharmacoeconomic parameters for NeoPulse in primary or recurrent squamous cell carcinoma of the skin, basal cell carcinoma as well as recurrent metastatic melanoma. Patients with primary or recurrent histologically confirmed tumors with no evidence of brain mestastases were eligible for enrollment. Safety and local control were measured. Patients received local injection of bleomycin follo
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Present at Upcoming Healthcare and Investor Conferences
2. OncoSec Granted New Patent from China
3. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
4. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
7. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
8. OncoSec Medical Issues Letter to Shareholders
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Filtrona Porous Technologies Introduces New Medical-Grade Foams And Unique Fiber Products For Clean Environments At MEDICA / COMPAMED Trade Fair
11. Rochester Medical Reports Record Fourth Quarter and Fiscal Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... 25, 2014 Thousands of transvaginal mesh ... in a number of multidistrict litigations currently underway in ... Liebhard LLP reports. According to an Order issued on ... a Joint Status Conference in all of the proceedings ... been directed to submit a proposed agenda to the ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 AlignLife of ... unable to afford certain items. During the holiday season, AlignLife ... collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of ... staff such joy, knowing that we are able to give ... had it not been for the generosity of our patients." ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... monitoring helped push cure rates to nearly 88 percent ... Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and ... battling the most common childhood cancer. A report ... of Clinical Oncology noted that overall survival jumped 30 ...
... News) -- Most head and neck cancer patients can ... treatment, but several factors may be associated with poor ... patients who were assessed nearly three years after they ... neck cancer. The U.S. researchers gave a speaking ...
... to develop genital cancer, especially as they grow older. ... sexes suffer from the condition, which is extremely difficult to ... of the similarity of the disease to human genital cancer ... Several human genital cancers, including cervical tumours, are known ...
... Nasal congestion can be a sign of severe asthma, ... when it comes to nasal complaints. Furthermore, more severe ... reveals a study from the Sahlgrenska Academy,s Krefting Research ... Respiratory Research , the population study included 30,000 randomly ...
... the effects of monensin emerged in a project investigating ... the growth of prostate cancer cells. The project involved ... found that small amounts of compounds disulfiram (Antabus), ... growth of prostate cancer cells without significant effects on ...
... The hectic pace of the holiday season can make it ... conditions to maintain normal routines and medication schedules. This can ... errors, according to the American Pain Foundation. But a ... over the holidays, the foundation says. If you,re traveling, ...
Cached Medicine News:Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 3Health News:Speech, Swallowing Usually OK After Head & Neck Cancer Therapy 2Health News:A possible cause -- and cure -- for genital cancer in horses? 2Health News:Nasal congestion can mean severe asthma 2Health News:Finnish researchers find a compound that prevents the growth of prostate cancer cells 2Health News:Hectic Holiday Pace Can Upset Medication Schedule 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: